MRC/UVRI & LSHTM Uganda Research Unit, Plot 51-59 Nakiwogo Road, Entebbe, Uganda.
London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
BMC Public Health. 2020 Nov 25;20(1):1789. doi: 10.1186/s12889-020-09932-7.
We anticipate large efficacy trials of novel HIV vaccines that have shown acceptable safety profiles. We determined willingness to participate (WTP) in future HIV vaccine efficacy trials among HIV negative female sex workers (FSWs) in Kampala Uganda.
We conducted a case control study in the Good Health for Women Project cohort. Cases received HIV prevention services and, enrolled in a 12-month simulated vaccine efficacy trial (SiVET) that used Hepatitis B vaccine; they underwent vaccine trial procedures as would be in an actual trial. Controls received similar health services but did not enroll in SiVET. We matched cases and controls (ratio 2:1) for age and duration in the cohort. We described a hypothetical HIV vaccine trial to cases (after 9 months in SiVET) and controls including trial attributes: randomization, delaying pregnancy, frequent blood draws (80-100mls) and study visits for 3 years. We compared WTP and willingness for vaccine trial attributes by case/control using chi-squared or Fisher's exact tests and fitted conditional logistic regression models to determine independent predictors of WTP.
We analyzed data for 311 volunteers (219 cases, 92 controls); median age 27 years (IQR: 23-32), 39.9% had ≥secondary education, 57.9% had sex work as their main job and 81.9% used illicit drugs. Compared to controls, more cases had lived in the community for > 1 year, (85.4% vs 64.1%; p < 0.001) and fewer cases reported illicit drug use in the past 3 months, (79.0% vs 89.1%; p = 0.03). Overall, 278 (89.4%) volunteers expressed WTP in an HIV vaccine trial, the most common reason being hope of protection against HIV. More cases than controls (58.2% vs 44.7%) did not need to consult anyone before trial participation (p = 0.03); cases were more willing to delay pregnancy (99.0% vs 94.0%; p = 0.03). Combining vaccine trial attributes, 249 (89.6%) of the 278 accepted all attributes. After controlling for case/ control status women with secondary education or higher expressed less WTP (aOR 0.17; 95% CI 0.04-0.80).
FSWs in Kampala demonstrated high WTP. Prior experience with trial requirements like contraception may improve their uptake during actual trials. Family involvement is important for those without prior trial experience.
我们预计将有大量新型 HIV 疫苗的疗效试验,这些试验已显示出可接受的安全性。我们确定了乌干达坎帕拉 HIV 阴性女性性工作者(FSW)对未来 HIV 疫苗疗效试验的参与意愿(WTP)。
我们在妇女健康项目队列中进行了病例对照研究。病例组接受 HIV 预防服务,并参加了为期 12 个月的模拟疫苗疗效试验(SiVET),该试验使用了乙肝疫苗;他们接受了与实际试验相同的疫苗试验程序。对照组接受了类似的健康服务,但未参加 SiVET。我们按照年龄和队列中的时间进行病例和对照组的匹配(比例为 2:1)。我们向病例组(在 SiVET 中 9 个月后)和对照组描述了一种假设的 HIV 疫苗试验,包括试验属性:随机化、延迟怀孕、频繁采血(80-100ml)和 3 年的研究访视。我们使用卡方检验或 Fisher 精确检验比较病例/对照的 WTP 和对疫苗试验属性的意愿,并拟合条件逻辑回归模型来确定 WTP 的独立预测因素。
我们分析了 311 名志愿者的数据(219 例病例,92 例对照);中位年龄 27 岁(IQR:23-32),39.9%受过中学以上教育,57.9%以性工作为主要职业,81.9%使用非法药物。与对照组相比,更多的病例在社区生活了>1 年(85.4%比 64.1%;p<0.001),过去 3 个月报告使用非法药物的病例更少(79.0%比 89.1%;p=0.03)。总体而言,278 名(89.4%)志愿者表示愿意参加 HIV 疫苗试验,最常见的原因是希望预防 HIV。与对照组相比,更多的病例在参与试验前不需要咨询任何人(58.2%比 44.7%;p=0.03);病例组更愿意延迟怀孕(99.0%比 94.0%;p=0.03)。综合疫苗试验属性,278 名接受试验的志愿者中有 249 名(89.6%)接受了所有属性。在校正病例/对照状态后,受过中学或更高教育的妇女表示不太愿意参与(aOR 0.17;95%CI 0.04-0.80)。
坎帕拉的 FSW 表现出很高的 WTP。在实际试验中,他们可能会根据对避孕等试验要求的先前经验来提高参与度。对于没有试验经验的人,家庭参与很重要。